Loading...

Mark Geyer

TitleRecall Faculty
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-3582
vCardDownload vCard

    Collapse Overview 
    Collapse Overview

    Biography

    Mark A. Geyer Ph.D. is the former Vice Chair for Research in Psychiatry and directs the Neuropsychopharmacology Unit of the VISN 22 VA’s Mental Illness Research, Clinical, and Education Center. He was involved intensively in the NIMH-funded MATRICS, TURNS, and CNTRICS Programs. Dr. Geyer is a pioneer in the translational study of sensorimotor gating deficits in schizophrenia and related animal models and has published over 425 peer-reviewed papers and many reviews, chapters, and edited books. He is the lead Series Editor for Current Topics in Behavioral Neurosciences, which has completed 16 volumes. His research program has been supported continuously by grants from NIMH and NIDA for 30+ years. He is Associate Editor of Neuropsychopharmacology, Fellow and Council Member of the ACNP, Fellow of AAAS and American Psychological Society, Past-President of the Serotonin Club, Past-President and Fellow of International Behavioral Neuroscience Society, member of Scientific Council of NARSAD, Scientific Advisor to European Union’s Innovative Medicine Initiative, and 2011 awardee of Bleuler Prize for Research in the Schizophrenias.

    Research Interests

    Dr. Geyer’s research group focuses on developing parallel behavioral paradigms in animals and humans for use in psychiatric drug discovery. For example, working with Dr. David Braff, Dr. Geyer published the first study demonstrating that prepulse inhibition (PPI) of startle, a measure of sensorimotor gating, is disrupted in schizophrenic patients in 1978. Since then, research in his laboratory has shown that PPI in animals is disrupted by a number of agents that are psychoactive in humans and in a number of lines of mutant mice. These findings led to the acceptance of PPI as an animal model related to schizophrenia and bipolar mania that reflects aspects of the disease states observed in patients. His translational group currently includes five faculty members, Drs. Susan Powell, Victoria Risbrough, Xianjin Zhou, Jared Young, and Adam Halberstadt. Our combined laboratories use behavioral measures and psychopharmacological manipulations in rodents and humans to examine the roles of neurotransmitters in behavior, to develop animal models of human drug effects, and to explore information-processing deficits in psychiatric disorders. We use startle measures of habituation, prepulse inhibition, anxiety potentiation, and fear extinction that are deficient in psychiatric disorders and can be mimicked in rodents by pharmacological, developmental, and genetic manipulations. Under Dr. Risbrough’s leadership, the group is using a battery of startle tests in a prospective longitudinal Marine Resilience Study, paralleled by neurobiological studies of CRF systems and stressors in rodents. Dr. Geyer has developed a Behavioral Pattern Monitor for use in rats, mice, and humans. These systems provide cross-species translational and multivariate assessments of spatio-temporal patterns of exploratory behavior and are being used in comparisons of schizophrenia and bipolar mania in relationship to corresponding animal models and the effects of psychostimulants in human volunteers. We have explored the effects of classical hallucinogens, dopaminergic psychostimulants, and both direct and indirect serotonin agonists to elucidate their respective mechanisms of action and to reveal the involvement of specific monoamine systems and receptors in behavioral responses to environmental stimuli and in processes such as arousal, habituation, and sensorimotor gating. Animal models of interest in the laboratory include pharmacological manipulations, a variety of developmental perturbations, and genetic models involving strain comparisons, knockouts, and humanized mutant mice, most of which are related to psychotic and/or stress-related disorders. A current focus of the laboratory is the development of murine tests of specific cognitive domains relevant to the MATRICS and CNTRICS efforts to treat cognitive deficits in psychiatric disorders.


    Collapse Research 
    Collapse Research Activities and Funding
    Early postnatal disruptions to glutamate and GABA systems and their contribution to reward deficits
    NIH/NIMH R01MH108653Jul 15, 2016 - Apr 30, 2021
    Role: Principal Investigator
    Serotonin Club IUPHAR Satellite Meeting
    NIH/NIMH R13MH078663Jul 1, 2006 - Jun 30, 2007
    Role: Principal Investigator
    Stress and CRF System Effects on Information Processing
    NIH/NIMH R01MH074697Jul 1, 2005 - Apr 30, 2015
    Role: Principal Investigator
    Sp4 Pathway in the Modulation of Sensorimotor Gating and Memory
    NIH/NIMH R01MH073991Dec 1, 2004 - Jul 31, 2015
    Role: Principal Investigator
    INHIBITORY DEFICITS IN HUMAN AND ANIMAL MODELS OF BIPOLAR DISORDER
    NIH/NIMH R01MH071916Aug 25, 2004 - Apr 30, 2015
    Role: Principal Investigator
    STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    NIH/NIMH R01MH061326Jun 1, 2000 - May 31, 2006
    Role: Principal Investigator
    Developmental Models of Gating Deficits in Schizophrenia
    NIH/NIMH R01MH052885Apr 1, 1995 - Apr 30, 2012
    Role: Principal Investigator
    LIMBIC MONOAMINES, BEHAVIOR, AND PSYCHOPATHOLOGY
    NIH/NIMH K05MH001223Sep 30, 1994 - Dec 31, 1999
    Role: Principal Investigator
    PREPULSE INHIBITION IN RATS REARED IN ISOLATION
    NIH/FIC F06TW001813Aug 4, 1993
    Role: Principal Investigator
    DRUGS OF ABUSE--COMPLEXITY MEASURES CLASSIFY BEHAVIOR
    NIH/NIDA R01DA006325Mar 1, 1990 - Feb 28, 1995
    Role: Principal Investigator
    LIMBIC MONOAMINES, BEHAVIOR, &PSYCHOPATHOLOGY
    NIH/NIMH K02MH000188Sep 1, 1983 - Aug 31, 1994
    Role: Principal Investigator
    HIPPOCAMPAL TRANSMITTER EFFICACY AFTER ANTIDEPRESSANTS
    NIH/NIMH R01MH037954Sep 1, 1983 - Mar 31, 1989
    Role: Principal Investigator
    Monoamine and Hallucinogen Effects on Rodent Behavior
    NIH/NIDA R01DA002925Sep 30, 1981 - Jan 31, 2016
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. MacQueen DA, Minassian A, Kenton JA, Geyer M, Perry W, Brigman JL, Young JW. Amphetamine improves mouse and human attention in the 5-choice continuous performance test. Neuropharmacology. 2018 May 31; 138:87-96. PMID: 29859849.
      View in: PubMed
    2. Geyer M, Semenova S, Li X, Der-Avakian A, Barnes SA, Grant I. Overview of the Biography and Legacy of Professor Athina Markou. Biol Psychiatry. 2018 Jun 01; 83(11):910-912. PMID: 29501205.
      View in: PubMed
    3. Phillips AG, Geyer M, Robbins TW. Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders. Biol Psychiatry. 2018 Jun 01; 83(11):915-923. PMID: 29478700.
      View in: PubMed
    4. Stout DM, Acheson DT, Moore TM, Gur RC, Baker DG, Geyer M, Risbrough VB. Individual variation in working memory is associated with fear extinction performance. Behav Res Ther. 2018 Mar; 102:52-59. PMID: 29331727.
      View in: PubMed
    5. Halberstadt AL, Geyer M. Effect of Hallucinogens on Unconditioned Behavior. Curr Top Behav Neurosci. 2018; 36:159-199. PMID: 28224459.
      View in: PubMed
    6. Kwiatkowski MA, Hellemann G, Sugar CA, Cope ZA, Minassian A, Perry W, Geyer M, Young JW. Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors. Pharmacol Biochem Behav. 2017 Dec 28. PMID: 29289701.
      View in: PubMed
    7. Minassian A, Young JW, Geyer M, Kelsoe JR, Perry W. The COMT Val158Met Polymorphism and Exploratory Behavior in Bipolar Mania. Mol Neuropsychiatry. 2018 Feb; 3(3):151-156. PMID: 29594134.
      View in: PubMed
    8. MacQueen DA, Minassian A, Henry BL, Geyer M, Young JW, Perry W. Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults. J Int Neuropsychol Soc. 2018 Mar; 24(3):283-293. PMID: 29032769.
      View in: PubMed
    9. Deslauriers J, Acheson DT, Maihofer AX, Nievergelt CM, Baker DG, Geyer M, Risbrough VB. COMT val158met polymorphism links to altered fear conditioning and extinction are modulated by PTSD and childhood trauma. Depress Anxiety. 2018 Jan; 35(1):32-42. PMID: 28833952.
      View in: PubMed
    10. Nolte IM, Munoz ML, Tragante V, Amare AT, Jansen R, Vaez A, von der Heyde B, Avery CL, Bis JC, Dierckx B, van Dongen J, Gogarten SM, Goyette P, Hernesniemi J, Huikari V, Hwang SJ, Jaju D, Kerr KF, Kluttig A, Krijthe BP, Kumar J, van der Laan SW, Lyytikäinen LP, Maihofer AX, Minassian A, van der Most PJ, Müller-Nurasyid M, Nivard M, Salvi E, Stewart JD, Thayer JF, Verweij N, Wong A, Zabaneh D, Zafarmand MH, Abdellaoui A, Albarwani S, Albert C, Alonso A, Ashar F, Auvinen J, Axelsson T, Baker DG, de Bakker PIW, Barcella M, Bayoumi R, Bieringa RJ, Boomsma D, Boucher G, Britton AR, Christophersen I, Dietrich A, Ehret GB, Ellinor PT, Eskola M, Felix JF, Floras JS, Franco OH, Friberg P, Gademan MGJ, Geyer M, Giedraitis V, Hartman CA, Hemerich D, Hofman A, Hottenga JJ, Huikuri H, Hutri-Kähönen N, Jouven X, Junttila J, Juonala M, Kiviniemi AM, Kors JA, Kumari M, Kuznetsova T, Laurie CC, Lefrandt JD, Li Y, Li Y, Liao D, Limacher MC, Lin HJ, Lindgren CM, Lubitz SA, Mahajan A, McKnight B, Zu Schwabedissen HM, Milaneschi Y, Mononen N, Morris AP, Nalls MA, Navis G, Neijts M, Nikus K, North KE, O'Connor DT, Ormel J, Perz S, Peters A, Psaty BM, Raitakari OT, Risbrough VB, Sinner MF, Siscovick D, Smit JH, Smith NL, Soliman EZ, Sotoodehnia N, Staessen JA, Stein PK, Stilp AM, Stolarz-Skrzypek K, Strauch K, Sundström J, Swenne CA, Syvänen AC, Tardif JC, Taylor KD, Teumer A, Thornton TA, Tinker LE, Uitterlinden AG, van Setten J, Voss A, Waldenberger M, Wilhelmsen KC, Willemsen G, Wong Q, Zhang ZM, Zonderman AB, Cusi D, Evans MK, Greiser HK, van der Harst P, Hassan M, Ingelsson E, Järvelin MR, Kääb S, Kähönen M, Kivimaki M, Kooperberg C, Kuh D, Lehtimäki T, Lind L, Nievergelt CM, O'Donnell CJ, Oldehinkel AJ, Penninx B, Reiner AP, Riese H, van Roon AM, Rioux JD, Rotter JI, Sofer T, Stricker BH, Tiemeier H, Vrijkotte TGM, Asselbergs FW, Brundel BJJM, Heckbert SR, Whitsel EA, den Hoed M, Snieder H, de Geus EJC. Erratum: Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nat Commun. 2017 Aug 02; 8:16140. PMID: 28767105.
      View in: PubMed
    11. Cope ZA, Minassian A, Kreitner D, MacQueen DA, Milienne-Petiot M, Geyer M, Perry W, Young JW. Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Neuropharmacology. 2017 Oct; 125:254-262. PMID: 28774856.
      View in: PubMed
    12. Nolte IM, Munoz ML, Tragante V, Amare AT, Jansen R, Vaez A, von der Heyde B, Avery CL, Bis JC, Dierckx B, van Dongen J, Gogarten SM, Goyette P, Hernesniemi J, Huikari V, Hwang SJ, Jaju D, Kerr KF, Kluttig A, Krijthe BP, Kumar J, van der Laan SW, Lyytikäinen LP, Maihofer AX, Minassian A, van der Most PJ, Müller-Nurasyid M, Nivard M, Salvi E, Stewart JD, Thayer JF, Verweij N, Wong A, Zabaneh D, Zafarmand MH, Abdellaoui A, Albarwani S, Albert C, Alonso A, Ashar F, Auvinen J, Axelsson T, Baker DG, de Bakker PIW, Barcella M, Bayoumi R, Bieringa RJ, Boomsma D, Boucher G, Britton AR, Christophersen I, Dietrich A, Ehret GB, Ellinor PT, Eskola M, Felix JF, Floras JS, Franco OH, Friberg P, Gademan MGJ, Geyer M, Giedraitis V, Hartman CA, Hemerich D, Hofman A, Hottenga JJ, Huikuri H, Hutri-Kähönen N, Jouven X, Junttila J, Juonala M, Kiviniemi AM, Kors JA, Kumari M, Kuznetsova T, Laurie CC, Lefrandt JD, Li Y, Li Y, Liao D, Limacher MC, Lin HJ, Lindgren CM, Lubitz SA, Mahajan A, McKnight B, Zu Schwabedissen HM, Milaneschi Y, Mononen N, Morris AP, Nalls MA, Navis G, Neijts M, Nikus K, North KE, O'Connor DT, Ormel J, Perz S, Peters A, Psaty BM, Raitakari OT, Risbrough VB, Sinner MF, Siscovick D, Smit JH, Smith NL, Soliman EZ, Sotoodehnia N, Staessen JA, Stein PK, Stilp AM, Stolarz-Skrzypek K, Strauch K, Sundström J, Swenne CA, Syvänen AC, Tardif JC, Taylor KD, Teumer A, Thornton TA, Tinker LE, Uitterlinden AG, van Setten J, Voss A, Waldenberger M, Wilhelmsen KC, Willemsen G, Wong Q, Zhang ZM, Zonderman AB, Cusi D, Evans MK, Greiser HK, van der Harst P, Hassan M, Ingelsson E, Järvelin MR, Kääb S, Kähönen M, Kivimaki M, Kooperberg C, Kuh D, Lehtimäki T, Lind L, Nievergelt CM, O'Donnell CJ, Oldehinkel AJ, Penninx B, Reiner AP, Riese H, van Roon AM, Rioux JD, Rotter JI, Sofer T, Stricker BH, Tiemeier H, Vrijkotte TGM, Asselbergs FW, Brundel BJJM, Heckbert SR, Whitsel EA, den Hoed M, Snieder H, de Geus EJC. Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nat Commun. 2017 Jun 14; 8:15805. PMID: 28613276.
      View in: PubMed
    13. Glenn DE, Acheson DT, Geyer M, Nievergelt CM, Baker DG, Risbrough VB. Fear learning alterations after traumatic brain injury and their role in development of posttraumatic stress symptoms. Depress Anxiety. 2017 08; 34(8):723-733. PMID: 28489272.
      View in: PubMed
    14. Milienne-Petiot M, Geyer M, Arnt J, Young JW. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar; 234(6):1017-1028. PMID: 28160035.
      View in: PubMed
    15. Deslauriers J, van Wijngaarde M, Geyer M, Powell S, Risbrough VB. Effects of LPS-induced immune activation prior to trauma exposure on PTSD-like symptoms in mice. Behav Brain Res. 2017 04 14; 323:117-123. PMID: 28159589.
      View in: PubMed
    16. Higa KK, Young JW, Ji B, Nichols DE, Geyer M, Zhou X. Striatal dopamine D1 receptor suppression impairs reward-associative learning. Behav Brain Res. 2017 04 14; 323:100-110. PMID: 28143767.
      View in: PubMed
    17. Geyer M. Athina Markou. Neuropsychopharmacology. 2016 Dec; 41(13):3121-3122. PMID: 27818512.
      View in: PubMed
    18. Ahmari SE, Risbrough VB, Geyer M, Simpson HB. Prepulse Inhibition Deficits in Obsessive-Compulsive Disorder are More Pronounced in Females. Neuropsychopharmacology. 2016 12; 41(13):2963-2964. PMID: 27818517.
      View in: PubMed
    19. Milienne-Petiot M, Kesby JP, Graves M, van Enkhuizen J, Semenova S, Minassian A, Markou A, Geyer M, Young JW. The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology. 2017 02; 113(Pt A):260-270. PMID: 27732870.
      View in: PubMed
    20. Swerdlow NR, Braff DL, Geyer M. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 11; 30(11):1072-1081. PMID: 27539931.
      View in: PubMed
    21. Cope ZA, Halberstadt AL, van Enkhuizen J, Flynn AD, Breier M, Swerdlow NR, Geyer M, Young JW. Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology (Berl). 2016 10; 233(19-20):3513-25. PMID: 27534540.
      View in: PubMed
    22. Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer M, Prinssen E, Ballard T, Macleod M. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nat Rev Drug Discov. 2016 Jul; 15(7):516. PMID: 27312728.
      View in: PubMed
    23. Halberstadt AL, Sindhunata IS, Scheffers K, Flynn AD, Sharp RF, Geyer M, Young JW. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016 08; 107:364-375. PMID: 27020041.
      View in: PubMed
    24. Glenn DE, Acheson DT, Geyer M, Nievergelt CM, Baker DG, Risbrough VB. HIGH AND LOW THRESHOLD FOR STARTLE REACTIVITY ASSOCIATED WITH PTSD SYMPTOMS BUT NOT PTSD RISK: EVIDENCE FROM A PROSPECTIVE STUDY OF ACTIVE DUTY MARINES. Depress Anxiety. 2016 Mar; 33(3):192-202. PMID: 26878585.
      View in: PubMed
    25. Steinman SA, Ahmari SE, Choo T, Kimeldorf MB, Feit R, Loh S, Risbrough V, Geyer M, Steinglass JE, Wall M, Schneier FR, Fyer AJ, Simpson HB. PREPULSE INHIBITION DEFICITS ONLY IN FEMALES WITH OBSESSIVE-COMPULSIVE DISORDER. Depress Anxiety. 2016 Mar; 33(3):238-46. PMID: 26878422; PMCID: PMC4806386 [Available on 03/01/17].
    26. Higa KK, Young JW, Geyer M. Wet or dry: translatable "water mazes" for mice and humans. J Clin Invest. 2016 Feb; 126(2):477-9. PMID: 26784538; PMCID: PMC4731183 [Available on 02/01/17].
    27. Yurgil KA, Clifford RE, Risbrough VB, Geyer M, Huang M, Barkauskas DA, Vasterling JJ. Prospective Associations Between Traumatic Brain Injury and Postdeployment Tinnitus in Active-Duty Marines. J Head Trauma Rehabil. 2016 Jan-Feb; 31(1):30-9. PMID: 25699623.
      View in: PubMed
    28. Young JW, Minassian A, Geyer M. Locomotor Profiling from Rodents to the Clinic and Back Again. Curr Top Behav Neurosci. 2016; 28:287-303. PMID: 27418071.
      View in: PubMed
    29. Toth M, Flandreau EI, Deslauriers J, Geyer M, Mansuy IM, Merlo Pich E, Risbrough VB. Overexpression of Forebrain CRH During Early Life Increases Trauma Susceptibility in Adulthood. Neuropsychopharmacology. 2016 May; 41(6):1681-90. PMID: 26538448.
      View in: PubMed
    30. Geyer M. Lysergic Acid Diethylamide and Psilocybin Revisited. Biol Psychiatry. 2015 Oct 15; 78(8):516-8. PMID: 26386624.
      View in: PubMed
    31. Minassian A, Young JW, Cope ZA, Henry BL, Geyer M, Perry W. Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology (Berl). 2016 Jan; 233(2):225-33. PMID: 26449721.
      View in: PubMed
    32. Minassian A, Maihofer AX, Baker DG, Nievergelt CM, Geyer M, Risbrough VB. Association of Predeployment Heart Rate Variability With Risk of Postdeployment Posttraumatic Stress Disorder in Active-Duty Marines. JAMA Psychiatry. 2015 Oct; 72(10):979-86. PMID: 26353072.
      View in: PubMed
    33. van Enkhuizen J, Geyer M, Minassian A, Perry W, Henry BL, Young JW. Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev. 2015 Nov; 58:4-18. PMID: 26297513; PMCID: PMC4684462 [Available on 11/01/16].
    34. van Enkhuizen J, Milienne-Petiot M, Geyer M, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology (Berl). 2015 Sep; 232(18):3455-67. PMID: 26141192; PMCID: PMC4537820.
    35. Higa KK, Ji B, Buell MR, Risbrough VB, Powell SB, Young JW, Geyer M, Zhou X. Restoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice. Int J Neuropsychopharmacol. 2015 Jun 02; 18(11):pyv063. PMID: 26037489; PMCID: PMC4756721.
    36. Powell SB, Khan A, Young JW, Scott CN, Buell MR, Caldwell S, Tsan E, de Jong LA, Acheson DT, Lucero J, Geyer M, Behrens MM. Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats. Dev Neurosci. 2015; 37(3):253-62. PMID: 26022788; PMCID: PMC4644772.
    37. Young JW, Kamenski ME, Higa KK, Light GA, Geyer M, Zhou X. GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology. 2015 Nov; 40(12):2715-26. PMID: 25907107; PMCID: PMC4864647 [Available on 11/01/16].
    38. Flandreau E, Risbrough V, Lu A, Ableitner M, Geyer M, Holsboer F, Deussing JM. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating. Psychoneuroendocrinology. 2015 Mar; 53:16-28. PMID: 25575243; PMCID: PMC4364548.
    39. Nievergelt CM, Maihofer AX, Mustapic M, Yurgil KA, Schork NJ, Miller MW, Logue MW, Geyer M, Risbrough VB, O'Connor DT, Baker DG. Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology. 2015 Jan; 51:459-71. PMID: 25456346.
      View in: PubMed
    40. van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer M. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol. 2015 Apr 15; 753:114-26. PMID: 25107282; PMCID: PMC4318788.
    41. van Enkhuizen J, Henry BL, Minassian A, Perry W, Milienne-Petiot M, Higa KK, Geyer M, Young JW. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology. 2014 Dec; 39(13):3112-22. PMID: 25005251; PMCID: PMC4229584.
    42. Ji B, Higa KK, Kim M, Zhou L, Young JW, Geyer M, Zhou X. Inhibition of protein translation by the DISC1-Boymaw fusion gene from a Scottish family with major psychiatric disorders. Hum Mol Genet. 2014 Nov 01; 23(21):5683-705. PMID: 24908665; PMCID: PMC4189903.
    43. Csomor PA, Preller KH, Geyer M, Studerus E, Huber T, Vollenweider FX. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry. Neuropsychopharmacology. 2014 Sep; 39(10):2485-96. PMID: 24801767; PMCID: PMC4138738.
    44. Minassian A, Geyer M, Baker DG, Nievergelt CM, O'Connor DT, Risbrough VB. Heart rate variability characteristics in a large group of active-duty marines and relationship to posttraumatic stress. Psychosom Med. 2014 May; 76(4):292-301. PMID: 24804881; PMCID: PMC4062545.
    45. Young JW, Ratty A, Dawe GS, Geyer M. Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia. Behav Neurosci. 2014 Aug; 128(4):460-7. PMID: 24708299; PMCID: PMC4107138.
    46. Amitai N, Young JW, Higa K, Sharp RF, Geyer M, Powell SB. Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cogn Affect Behav Neurosci. 2014 Mar; 14(1):388-406. PMID: 23943516; PMCID: PMC3923850.
    47. Patt VM, Thomas ML, Minassian A, Geyer M, Brown GG, Perry W. Disentangling working memory processes during spatial span assessment: a modeling analysis of preferred eye movement strategies. J Clin Exp Neuropsychol. 2014; 36(2):186-204. PMID: 24499103; PMCID: PMC3970432.
    48. Henry BL, Geyer M, Buell MR, Perry W, Young JW, Minassian A. Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol. 2014 Feb; 25(1):12-22. PMID: 24281153; PMCID: PMC3926694.
    49. van Enkhuizen J, Acheson D, Risbrough V, Drummond S, Geyer M, Young JW. Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice. Behav Brain Res. 2014 Mar 15; 261:40-8. PMID: 24333377; PMCID: PMC3937379.
    50. Toth M, Gresack JE, Bangasser DA, Plona Z, Valentino RJ, Flandreau EI, Mansuy IM, Merlo-Pich E, Geyer M, Risbrough VB. Forebrain-specific CRF overproduction during development is sufficient to induce enduring anxiety and startle abnormalities in adult mice. Neuropsychopharmacology. 2014 May; 39(6):1409-19. PMID: 24326400.
      View in: PubMed
    51. van Enkhuizen J, Geyer M, Halberstadt AL, Zhuang X, Young JW. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord. 2014 Feb; 155:247-54. PMID: 24287168; PMCID: PMC3924859.
    52. Devor A, Bandettini PA, Boas DA, Bower JM, Buxton RB, Cohen LB, Dale AM, Einevoll GT, Fox PT, Franceschini MA, Friston KJ, Fujimoto JG, Geyer M, Greenberg JH, Halgren E, Hämäläinen MS, Helmchen F, Hyman BT, Jasanoff A, Jernigan TL, Judd LL, Kim SG, Kleinfeld D, Kopell NJ, Kutas M, Kwong KK, Larkum ME, Lo EH, Magistretti PJ, Mandeville JB, Masliah E, Mitra PP, Mobley WC, Moskowitz MA, Nimmerjahn A, Reynolds JH, Rosen BR, Salzberg BM, Schaffer CB, Silva GA, So PT, Spitzer NC, Tootell RB, Van Essen DC, Vanduffel W, Vinogradov SA, Wald LL, Wang LV, Weber B, Yodh AG. The challenge of connecting the dots in the B.R.A.I.N. Neuron. 2013 Oct 16; 80(2):270-4. PMID: 24139032.
      View in: PubMed
    53. Moore H, Geyer M, Carter CS, Barch DM. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev. 2013 Nov; 37(9 Pt B):2087-91. PMID: 24090823; PMCID: PMC3965347.
    54. Dean B, Moller HJ, Svensson TH, Geyer M, Rujescu D, Scarr E, Millan MJ. Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank. Int J Neuropsychopharmacol. 2014 Jan; 17(1):137-48. PMID: 24063634.
      View in: PubMed
    55. Halberstadt AL, Geyer M. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014 Feb; 77:200-7. PMID: 24012658; PMCID: PMC3866097.
    56. Halberstadt AL, Geyer M. Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol. 2013 Nov; 16(10):2165-80. PMID: 23942028; PMCID: PMC3928979.
    57. Siegel SJ, Talpos JC, Geyer M. Animal models and measures of perceptual processing in schizophrenia. Neurosci Biobehav Rev. 2013 Nov; 37(9 Pt B):2092-8. PMID: 23867801; PMCID: PMC3849201.
    58. Young JW, Geyer M. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013 Oct 15; 86(8):1122-32. PMID: 23856289; PMCID: PMC3797190.
    59. Ji B, Wang X, Pinto-Duarte A, Kim M, Caldwell S, Young JW, Behrens MM, Sejnowski TJ, Geyer M, Zhou X. Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia. PLoS One. 2013; 8(6):e66327. PMID: 23823008; PMCID: PMC3688895.
    60. Henry BL, Minassian A, Patt VM, Hua J, Young JW, Geyer M, Perry W. Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. J Affect Disord. 2013 Sep 25; 150(3):948-54. PMID: 23759280; PMCID: PMC3759601.
    61. Minassian A, Henry BL, Woods SP, Vaida F, Grant I, Geyer M, Perry W. Prepulse inhibition in HIV-associated neurocognitive disorders. J Int Neuropsychol Soc. 2013 Jul; 19(6):709-17. PMID: 23552464; PMCID: PMC3729041.
    62. Liu X, Hong SI, Park SJ, Dela Peña JB, Che H, Yoon SY, Kim DH, Kim JM, Cai M, Risbrough V, Geyer M, Shin CY, Cheong JH, Park H, Lew JH, Ryu JH. The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice. Arch Pharm Res. 2013 Jul; 36(7):854-63. PMID: 23543630.
      View in: PubMed
    63. Halberstadt AL, Geyer M. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl). 2013 Jun; 227(4):727-39. PMID: 23407781; PMCID: PMC3866102.
    64. Halberstadt AL, Powell SB, Geyer M. Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology. 2013 Jul; 70:218-27. PMID: 23376711; PMCID: PMC3934507.
    65. Young JW, Meves JM, Geyer M. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res. 2013 Mar 01; 240:119-33. PMID: 23201359; PMCID: PMC3538919.
    66. van Enkhuizen J, Geyer M, Kooistra K, Young JW. Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1021-31. PMID: 23164454; PMCID: PMC3920978.
    67. Holstein DH, Vollenweider FX, Geyer M, Csomor PA, Belser N, Eich D. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2013 Jan 30; 205(1-2):117-26. PMID: 23017654.
      View in: PubMed
    68. van Enkhuizen J, Geyer M, Young JW. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl). 2013 Feb; 225(3):661-74. PMID: 22945515; PMCID: PMC3537839.
    69. Henry BL, Geyer M, Buell M, Perry W, Young JW, Minassian A. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res. 2013 Jan 01; 236(1):210-20. PMID: 22960458; PMCID: PMC3482284.
    70. Geyer M, Olivier B, Joëls M, Kahn RS. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol Sci. 2012 Oct; 33(10):515-21. PMID: 22810174; PMCID: PMC3461097.
    71. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer M, Braff DL. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
      View in: PubMed
    72. Baker DG, Nash WP, Litz BT, Geyer M, Risbrough VB, Nievergelt CM, O'Connor DT, Larson GE, Schork NJ, Vasterling JJ, Hammer PS, Webb-Murphy JA. Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis. 2012; 9:E97. PMID: 22575082; PMCID: PMC3431952.
    73. Swerdlow NR, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, Geyer M, Stevens KE, Powell SB. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci. 2012; 34(2-3):240-9. PMID: 22572564.
      View in: PubMed
    74. Acheson DT, Stein MB, Paulus MP, Geyer M, Risbrough VB. The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice. Neuropharmacology. 2012 Sep; 63(3):480-5. PMID: 22575075; PMCID: PMC3572212.
    75. Tanaka S, Young JW, Halberstadt AL, Masten VL, Geyer M. Four factors underlying mouse behavior in an open field. Behav Brain Res. 2012 Jul 15; 233(1):55-61. PMID: 22569582; PMCID: PMC3866095.
    76. Halberstadt AL, Buell MR, Price DL, Geyer M. Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. Pharmacol Biochem Behav. 2012 Jul; 102(1):88-94. PMID: 22487771; PMCID: PMC3354037.
    77. Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer M, Goodwin GM, Gorwood P, Jay TM, Joëls M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012 Feb 01; 11(2):141-68. PMID: 22293568.
      View in: PubMed
    78. Halberstadt AL, Nichols DE, Geyer M. Behavioral effects of a,a,ß,ß-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology (Berl). 2012 Jun; 221(4):709-18. PMID: 22222861; PMCID: PMC3796951.
    79. Ahmari SE, Risbrough VB, Geyer M, Simpson HB. Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology. 2012 Apr; 37(5):1216-23. PMID: 22218093; PMCID: PMC3306882.
    80. Young JW, Amitai N, Geyer M. Behavioral animal models to assess pro-cognitive treatments for schizophrenia. Handb Exp Pharmacol. 2012; (213):39-79. PMID: 23027412.
      View in: PubMed
    81. Powell SB, Weber M, Geyer M. Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci. 2012; 12:251-318. PMID: 22367921; PMCID: PMC3357439.
    82. George D, El-Mallawany NK, Jin Z, Geyer M, Della-Latta P, Satwani P, Garvin JH, Bradley MB, Bhatia M, van de Ven C, Morris E, Schwartz J, Cairo MS. Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality. Br J Haematol. 2012 Jan; 156(1):99-108. PMID: 22008222.
      View in: PubMed
    83. Young JW, Henry BL, Geyer M. Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol. 2011 Oct; 164(4):1263-84. PMID: 21410454; PMCID: PMC3229761.
    84. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer M, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011 Oct; 1236:30-43. PMID: 22032400; PMCID: PMC3787879.
    85. Quednow BB, Kometer M, Geyer M, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012 Feb; 37(3):630-40. PMID: 21956447; PMCID: PMC3260978.
    86. Holstein DH, Csomor PA, Geyer M, Huber T, Brugger N, Studerus E, Vollenweider FX. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol. 2011 Dec; 25(12):1600-13. PMID: 21890590.
      View in: PubMed
    87. Butler PD, Chen Y, Ford JM, Geyer M, Silverstein SM, Green MF. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull. 2012 Jan; 38(1):81-91. PMID: 21890745; PMCID: PMC3245585.
    88. Minassian A, Henry BL, Young JW, Masten V, Geyer M, Perry W. Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS One. 2011; 6(8):e24185. PMID: 21912623.
      View in: PubMed
    89. Tanaka S, Young JW, Gresack JE, Geyer M, Risbrough VB. Factor analysis of attentional set-shifting performance in young and aged mice. Behav Brain Funct. 2011 Aug 12; 7:33. PMID: 21838910; PMCID: PMC3174878.
    90. Chung S, Verheij MM, Hesseling P, van Vugt RW, Buell M, Belluzzi JD, Geyer M, Martens GJ, Civelli O. The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS One. 2011; 6(7):e19286. PMID: 21818251; PMCID: PMC3139593.
    91. Young JW, Powell SB, Geyer M. Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology. 2012 Mar; 62(3):1381-90. PMID: 21726569; PMCID: PMC3217063.
    92. Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, Cohen JD, Geyer M, Gollub R, Green MF, Jaeger J, Krystal JH, Moore H, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry. 2011 Jul 01; 70(1):7-12. PMID: 21529781; PMCID: PMC3116022.
    93. Young JW, Powell SB, Scott CN, Zhou X, Geyer M. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res. 2011 Sep 12; 222(1):183-92. PMID: 21458500; PMCID: PMC3531561.
    94. Young JW, van Enkhuizen J, Winstanley CA, Geyer M. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol. 2011 Jul; 25(7):934-43. PMID: 21421642; PMCID: PMC3568506.
    95. Young JW, Kooistra K, Geyer M. Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology. 2011 Jun; 36(7):1385-96. PMID: 21412225; PMCID: PMC3096808.
    96. Henry BL, Minassian A, van Rhenen M, Young JW, Geyer M, Perry W. Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology (Berl). 2011 Jun; 215(4):697-707. PMID: 21279333.
      View in: PubMed
    97. Halberstadt AL, Geyer M. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011 Sep; 61(3):364-81. PMID: 21256140; PMCID: PMC3110631.
    98. Tarantino IS, Sharp RF, Geyer M, Meves JM, Young JW. Working memory span capacity improved by a D2 but not D1 receptor family agonist. Behav Brain Res. 2011 Jun 01; 219(2):181-8. PMID: 21232557; PMCID: PMC3073724.
    99. Halberstadt AL, Lehmann-Masten VD, Geyer M, Powell SB. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice. Psychopharmacology (Berl). 2011 May; 215(1):81-92. PMID: 21153406; PMCID: PMC3072483.
    100. Halberstadt AL, Koedood L, Powell SB, Geyer M. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011 Nov; 25(11):1548-61. PMID: 21148021; PMCID: PMC3531560.
    101. Ali SS, Young JW, Wallace CK, Gresack J, Jeste DV, Geyer M, Dugan LL, Risbrough VB. Initial evidence linking synaptic superoxide production with poor short-term memory in aged mice. Brain Res. 2011 Jan 12; 1368:65-70. PMID: 21075081; PMCID: PMC3018762.
    102. Semenova S, Hoyer D, Geyer M, Markou A. Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats. Neuropeptides. 2010 Oct; 44(5):421-9. PMID: 20537385; PMCID: PMC3215674.
    103. Bailer UF, Bloss CS, Frank GK, Price JC, Meltzer CC, Mathis CA, Geyer M, Wagner A, Becker CR, Schork NJ, Kaye WH. 5-HT1A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. Int J Eat Disord. 2011 Sep; 44(6):477-87. PMID: 20872754; PMCID: PMC4286242.
    104. Markou A, Geyer M. Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry. 2010 Sep 15; 68(6):500-2. PMID: 20797461; PMCID: PMC2929529.
    105. Zhou X, Nie Z, Roberts A, Zhang D, Sebat J, Malhotra D, Kelsoe JR, Geyer M. Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet. 2010 Oct 01; 19(19):3797-805. PMID: 20634195; PMCID: PMC2935857.
    106. Perry W, Minassian A, Henry B, Kincaid M, Young JW, Geyer M. Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res. 2010 Jun 30; 178(1):84-91. PMID: 20471103; PMCID: PMC2914139.
    107. Gresack J, Powell S, Geyer M, Poore MS, Coste S, Risbrough V. CRF2 null mutation increases sensitivity to isolation rearing effects on locomotor activity in mice. Neuropeptides. 2010 Aug; 44(4):349-53. PMID: 20466421; PMCID: PMC2888500.
    108. Young JW, Powell SB, Geyer M, Jeste DV, Risbrough VB. The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci. 2010 May; 10(2):243-51. PMID: 20498348; PMCID: PMC2877277.
    109. Henry BL, Minassian A, Young JW, Paulus MP, Geyer M, Perry W. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev. 2010 Jul; 34(8):1296-306. PMID: 20398694; PMCID: PMC2900445.
    110. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer M. The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav. 2010 Jul; 96(1):7-15. PMID: 20363246; PMCID: PMC2878916.
    111. Chang WL, Geyer M, Buell MR, Weber M, Swerdlow NR. The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol. 2010 Mar; 21(2):135-43. PMID: 20215963; PMCID: PMC2890261.
    112. Young JW, Geyer M. Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry. 2010 Apr 15; 67(8):784-7. PMID: 20132929; PMCID: PMC2849918.
    113. Young JW, Wallace CK, Geyer M, Risbrough VB. Age-associated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci. 2010 Feb; 124(1):133-140. PMID: 20141288; PMCID: PMC3088993.
    114. Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, Geyer M, Powell SB. Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res. 2010 May 01; 209(1):80-4. PMID: 20097235; PMCID: PMC2832092.
    115. Young JW, Zhou X, Geyer M. Animal models of schizophrenia. Curr Top Behav Neurosci. 2010; 4:391-433. PMID: 21312408.
      View in: PubMed
    116. Minassian A, Henry BL, Geyer M, Paulus MP, Young JW, Perry W. The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord. 2010 Jan; 120(1-3):200-6. PMID: 19435640; PMCID: PMC2795051.
    117. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer M. GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl). 2010 Feb; 208(3):443-54. PMID: 20020109; PMCID: PMC2806531.
    118. Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer M, Vollenweider FX, Feldon J, Cattapan-Ludewig K. Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients. Neuropsychobiology. 2010; 61(2):79-86. PMID: 20016226; PMCID: PMC2837882.
    119. Halberstadt AL, Geyer M. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. Psychopharmacology (Berl). 2010 Feb; 208(2):179-89. PMID: 19937319.
      View in: PubMed
    120. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Zhuang X, Masten VL, Sharp RF, Geyer M. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry. 2009 Oct; 66(10):1072-80. PMID: 19805697; PMCID: PMC2897252.
    121. Henry BL, Minassian A, Paulus MP, Geyer M, Perry W. Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res. 2010 Feb; 44(3):168-76. PMID: 19700172; PMCID: PMC2822123.
    122. Suzuki G, Harper KM, Hiramoto T, Funke B, Lee M, Kang G, Buell M, Geyer M, Kucherlapati R, Morrow B, Männistö PT, Agatsuma S, Hiroi N. Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet. 2009 Oct 15; 18(20):3914-25. PMID: 19617637; PMCID: PMC2748897.
    123. Ruderman MA, Powell SB, Geyer M. A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice. J Young Investig. 2009 Jul 01; 19(13):1-7. PMID: 25346645.
      View in: PubMed
    124. Duvvuri V, Risbrough VB, Kaye WH, Geyer M. 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition. Pharmacol Biochem Behav. 2009 Sep; 93(3):349-53. PMID: 19490926; PMCID: PMC2724836.
    125. Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, Gold L, Meltzer LT, Azar MR, Geyer M, Shahid M. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl). 2009 Nov; 206(4):699-714. PMID: 19462162; PMCID: PMC2755103.
    126. Powell SB, Zhou X, Geyer M. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res. 2009 Dec 07; 204(2):282-94. PMID: 19397931; PMCID: PMC2735602.
    127. Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer M, Kelsoe JR. Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One. 2009; 4(4):e5196. PMID: 19401786; PMCID: PMC2674320.
    128. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer M, Powell SB. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009 Jul; 34(8):1958-67. PMID: 19322172; PMCID: PMC2697271.
    129. Young JW, Powell SB, Risbrough V, Marston HM, Geyer M. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009 May; 122(2):150-202. PMID: 19269307; PMCID: PMC2688712.
    130. Suzuki G, Harper KM, Hiramoto T, Sawamura T, Lee M, Kang G, Tanigaki K, Buell M, Geyer M, Trimble WS, Agatsuma S, Hiroi N. Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Hum Mol Genet. 2009 May 01; 18(9):1652-60. PMID: 19240081; PMCID: PMC2733818.
    131. Young JW, Light GA, Marston HM, Sharp R, Geyer M. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One. 2009; 4(1):e4227. PMID: 19156216; PMCID: PMC2626630.
    132. Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, Green MF, Krystal JH, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull. 2009 Jan; 35(1):109-14. PMID: 19023126; PMCID: PMC2643950.
    133. Green MF, Butler PD, Chen Y, Geyer M, Silverstein S, Wynn JK, Yoon JH, Zemon V. Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull. 2009 Jan; 35(1):163-81. PMID: 19023123; PMCID: PMC2635893.
    134. Risbrough VB, Geyer M, Hauger RL, Coste S, Stenzel-Poore M, Wurst W, Holsboer F. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology. 2009 May; 34(6):1494-503. PMID: 19020499; PMCID: PMC2900918.
    135. Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer M, Hen R, Dulawa SC. Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry. 2009 Mar 01; 65(5):401-8. PMID: 19013555; PMCID: PMC2674010.
    136. Rankin CH, Abrams T, Barry RJ, Bhatnagar S, Clayton DF, Colombo J, Coppola G, Geyer M, Glanzman DL, Marsland S, McSweeney FK, Wilson DA, Wu CF, Thompson RF. Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem. 2009 Sep; 92(2):135-8. PMID: 18854219; PMCID: PMC2754195.
    137. Markou A, Chiamulera C, Geyer M, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 2009 Jan; 34(1):74-89. PMID: 18830240; PMCID: PMC2651739.
    138. Powell SB, Young JW, Ong JC, Caron MG, Geyer M. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol. 2008 Sep; 19(5-6):562-5. PMID: 18690110; PMCID: PMC2693185.
    139. Geyer M, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008 Sep; 29(9):445-53. PMID: 19086254.
      View in: PubMed
    140. Geyer M. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res. 2008 Aug; 14(1):71-8. PMID: 18790726; PMCID: PMC2667110.
    141. Halberstadt AL, Geyer M. Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors. Neurobiol Learn Mem. 2009 Sep; 92(2):243-8. PMID: 18644244; PMCID: PMC2745310.
    142. Halberstadt AL, Buell MR, Masten VL, Risbrough VB, Geyer M. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl). 2008 Nov; 201(1):55-66. PMID: 18604652; PMCID: PMC2929165.
    143. Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry. 2008 Jul 01; 64(1):4-10. PMID: 18466880; PMCID: PMC2577821.
    144. Kumari V, Antonova E, Geyer M. Prepulse inhibition and "psychosis-proneness" in healthy individuals: an fMRI study. Eur Psychiatry. 2008 Jun; 23(4):274-80. PMID: 18222069.
      View in: PubMed
    145. Kumari V, Fannon D, Geyer M, Premkumar P, Antonova E, Simmons A, Kuipers E. Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex. 2008 Oct; 44(9):1206-14. PMID: 18761134.
      View in: PubMed
    146. Doherty JM, Masten VL, Powell SB, Ralph RJ, Klamer D, Low MJ, Geyer M. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology. 2008 Oct; 33(11):2648-56. PMID: 18075489.
      View in: PubMed
    147. Jonkman S, Risbrough VB, Geyer M, Markou A. Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology. 2008 Aug; 33(9):2131-8. PMID: 18033237; PMCID: PMC2648847.
    148. Kask K, Gulinello M, Bäckström T, Geyer M, Sundström-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology. 2008 Aug; 33(9):2283-90. PMID: 17940552.
      View in: PubMed
    149. Geyer M, Tamminga CA. Wayne Fenton's impact on academic neuroscience. Schizophr Bull. 2007 Sep; 33(5):1156-9. PMID: 17617663; PMCID: PMC2632348.
    150. Young JW, Minassian A, Paulus MP, Geyer M, Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev. 2007; 31(6):882-96. PMID: 17706782; PMCID: PMC2025688.
    151. Semenova S, Geyer M, Sutcliffe JG, Markou A, Hedlund PB. Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry. 2008 Jan 01; 63(1):98-105. PMID: 17531208; PMCID: PMC2174622.
    152. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer M, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology. 2008 Feb; 33(3):497-512. PMID: 17460616.
      View in: PubMed
    153. Powell SB, Geyer M. Overview of animal models of schizophrenia. Curr Protoc Neurosci. 2007 Apr; Chapter 9:Unit 9.24. PMID: 18428667.
      View in: PubMed
    154. Abel KM, Allin M, van Amelsvoort T, Hemsley D, Geyer M. The indirect serotonergic agonist d-fenfluramine and prepulse inhibition in healthy men. Neuropharmacology. 2007 Mar; 52(4):1088-94. PMID: 17306313.
      View in: PubMed
    155. Vollenweider FX, Csomor PA, Knappe B, Geyer M, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007 Sep; 32(9):1876-87. PMID: 17299516.
      View in: PubMed
    156. Vinkers CH, Risbrough VB, Geyer M, Caldwell S, Low MJ, Hauger RL. Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating. Pharmacol Biochem Behav. 2007 Mar; 86(3):550-8. PMID: 17324452; PMCID: PMC1892615.
    157. Geyer M. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotox Res. 2006 Dec; 10(3-4):211-20. PMID: 17197371; PMCID: PMC2667105.
    158. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer M. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl). 2006 Dec; 189(3):319-29. PMID: 17013638.
      View in: PubMed
    159. McDowell JE, Brown GG, Lazar N, Camchong J, Sharp R, Krebs-Thomson K, Eyler LT, Braff DL, Geyer M. The neural correlates of habituation of response to startling tactile stimuli presented in a functional magnetic resonance imaging environment. Psychiatry Res. 2006 Nov 22; 148(1):1-10. PMID: 17000088.
      View in: PubMed
    160. Kumari V, Antonova E, Geyer M, Ffytche D, Williams SC, Sharma T. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol. 2007 Aug; 10(4):463-77. PMID: 16923324.
      View in: PubMed
    161. Oranje B, Geyer M, Bocker KB, Leon Kenemans J, Verbaten MN. Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res. 2006 Aug 30; 143(2-3):147-58. PMID: 16879870.
      View in: PubMed
    162. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer M. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology. 2006 Nov; 31(11):2349-58. PMID: 16855533.
      View in: PubMed
    163. Barr AM, Powell SB, Markou A, Geyer M. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology. 2006 Sep; 51(3):457-65. PMID: 16762376.
      View in: PubMed
    164. Moore H, Jentsch JD, Ghajarnia M, Geyer M, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006 Aug 01; 60(3):253-64. PMID: 16581031; PMCID: PMC3396156.
    165. Swerdlow NR, Geyer M, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772; PMCID: PMC1373667.
    166. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer M, Tolf BR, Brann MR, Davis RE. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May; 317(2):910-8. PMID: 16469866.
      View in: PubMed
    167. Postma P, Gray JA, Sharma T, Geyer M, Mehrotra R, Das M, Zachariah E, Hines M, Williams SC, Kumari V. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl). 2006 Mar; 184(3-4):589-99. PMID: 16456657.
      View in: PubMed
    168. Varty GB, Powell SB, Lehmann-Masten V, Buell MR, Geyer M. Isolation rearing of mice induces deficits in prepulse inhibition of the startle response. Behav Brain Res. 2006 Apr 25; 169(1):162-7. PMID: 16406103.
      View in: PubMed
    169. Geyer M. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci. 2006; 8(1):9-16. PMID: 16640109; PMCID: PMC3181759.
    170. Geyer M, Heinssen R. New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr Bull. 2005 Oct; 31(4):806-9. PMID: 16166608.
      View in: PubMed
    171. Ong JC, Brody SA, Large CH, Geyer M. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther. 2005 Dec; 315(3):1163-71. PMID: 16123308.
      View in: PubMed
    172. Floresco SB, Geyer M, Gold LH, Grace AA. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull. 2005 Oct; 31(4):888-94. PMID: 16079387.
      View in: PubMed
    173. de Jongh R, Geyer M, Olivier B, Groenink L. The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle. Behav Brain Res. 2005 Jun 20; 161(2):190-6. PMID: 15878207.
      View in: PubMed
    174. Meincke U, Light GA, Geyer M, Braff DL. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. PMID: 15942260.
      View in: PubMed
    175. Brody SA, Nakanishi N, Tu S, Lipton SA, Geyer M. A developmental influence of the N-methyl-D-aspartate receptor NR3A subunit on prepulse inhibition of startle. Biol Psychiatry. 2005 May 15; 57(10):1147-52. PMID: 15866554.
      View in: PubMed
    176. Powell SB, Palomo J, Carasso BS, Bakshi VP, Geyer M. Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Psychopharmacology (Berl). 2005 Jul; 180(3):491-500. PMID: 15719216.
      View in: PubMed
    177. Risbrough VB, Geyer M. Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry. 2005 Jan 01; 57(1):33-43. PMID: 15607298.
      View in: PubMed
    178. Ludewig S, Geyer M, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K. Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci. 2005 Jan; 30(1):37-43. PMID: 15644996; PMCID: PMC543839.
    179. Meincke U, Mörth D, Voss T, Thelen B, Geyer M, Gouzoulis-Mayfrank E. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study. Eur Arch Psychiatry Clin Neurosci. 2004 Dec; 254(6):415-21. PMID: 15538598.
      View in: PubMed
    180. Harte MK, Powell SB, Reynolds LM, Swerdlow NR, Geyer M, Reynolds GP. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. Biol Psychiatry. 2004 Aug 15; 56(4):296-9. PMID: 15312819.
      View in: PubMed
    181. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004 Aug 15; 56(4):255-60. PMID: 15312813.
      View in: PubMed
    182. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer M. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci. 2004 Jul 21; 24(29):6545-52. PMID: 15269266.
      View in: PubMed
    183. Powell SB, Geyer M, Gallagher D, Paulus MP. The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behav Brain Res. 2004 Jul 09; 152(2):341-9. PMID: 15196802.
      View in: PubMed
    184. Meincke U, Light GA, Geyer M, Braff DL, Gouzoulis-Mayfrank E. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. PMID: 15081627.
      View in: PubMed
    185. Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer M. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology. 2004 Feb; 29(2):221-8. PMID: 14603268.
      View in: PubMed
    186. Powell SB, Lehmann-Masten VD, Paulus MP, Gainetdinov RR, Caron MG, Geyer M. MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berl). 2004 May; 173(3-4):310-7. PMID: 14747902.
      View in: PubMed
    187. Heekeren K, Daumann J, Geyer M, Gouzoulis-Mayfrank E. Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. Psychopharmacology (Berl). 2004 May; 173(3-4):418-24. PMID: 14722707.
      View in: PubMed
    188. Heekeren K, Meincke U, Geyer M, Gouzoulis-Mayfrank E. Attentional modulation of prepulse inhibition: a new startle paradigm. Neuropsychobiology. 2004; 49(2):88-93. PMID: 14981340.
      View in: PubMed
    189. Brody SA, Geyer M. Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res. 2004; 6(1):79-90. PMID: 15184109.
      View in: PubMed
    190. Geyer M, Dulawa SC. Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci. 2003 Nov; Chapter 8:Unit 8.17. PMID: 18428584.
      View in: PubMed
    191. Dirks A, Groenink L, Westphal KG, Olivier JD, Verdouw PM, van der Gugten J, Geyer M, Olivier B. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology. 2003 Oct; 28(10):1790-8. PMID: 12865891.
      View in: PubMed
    192. Geyer M, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct; 27(7):1071-9. PMID: 14642967.
      View in: PubMed
    193. Harvey PD, Geyer M, Robbins TW, Krystal JH. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology (Berl). 2003 Sep; 169(3-4):213-4. PMID: 12955286.
      View in: PubMed
    194. Ludewig K, Geyer M, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry. 2003 Jul 15; 54(2):121-8. PMID: 12873801.
      View in: PubMed
    195. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer M. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl). 2003 Nov; 170(2):178-87. PMID: 12845406.
      View in: PubMed
    196. Ludewig K, Ludewig S, Seitz A, Obrist M, Geyer M, Vollenweider FX. The acoustic startle reflex and its modulation: effects of age and gender in humans. Biol Psychol. 2003 Jul; 63(3):311-23. PMID: 12853174.
      View in: PubMed
    197. Abel KM, Allin MP, Hemsley DR, Geyer M. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology. 2003 May; 44(6):729-37. PMID: 12681371.
      View in: PubMed
    198. Brody SA, Geyer M, Large CH. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl). 2003 Sep; 169(3-4):240-6. PMID: 12698229.
      View in: PubMed
    199. Ellwanger J, Geyer M, Braff DL. The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol. 2003 Mar; 62(3):175-95. PMID: 12633977.
      View in: PubMed
    200. Powell SB, Paulus MP, Hartman DS, Godel T, Geyer M. RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology. 2003 Mar; 44(4):473-81. PMID: 12646284.
      View in: PubMed
    201. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer M. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry. 2003 Feb 15; 53(4):352-9. PMID: 12586455.
      View in: PubMed
    202. Kumari V, Gray JA, Geyer M, ffytche D, Soni W, Mitterschiffthaler MT, Vythelingum GN, Simmons A, Williams SC, Sharma T. Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res. 2003 Feb 15; 122(2):99-113. PMID: 12714174.
      View in: PubMed
    203. Ralph-Williams RJ, Lehmann-Masten V, Geyer M. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology. 2003 Jan; 28(1):108-18. PMID: 12496946.
      View in: PubMed
    204. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer M. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci. 2002 Nov 01; 22(21):9604-11. PMID: 12417685.
      View in: PubMed
    205. Risbrough VB, Brodkin JD, Geyer M. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology. 2003 Apr; 28(4):654-63. PMID: 12655310.
      View in: PubMed
    206. Powell SB, Swerdlow NR, Pitcher LK, Geyer M. Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiol Behav. 2002 Sep; 77(1):55-64. PMID: 12213502.
      View in: PubMed
    207. Powell SB, Geyer M. Developmental markers of psychiatric disorders as identified by sensorimotor gating. Neurotox Res. 2002 Aug-Sep; 4(5-6):489-502. PMID: 12754162.
      View in: PubMed
    208. Swerdlow NR, Shoemaker JM, Stephany N, Wasserman L, Ro HJ, Geyer M. Prestimulus effects on startle magnitude: sensory or motor? Behav Neurosci. 2002 Aug; 116(4):672-81. PMID: 12148934.
      View in: PubMed
    209. Cadenhead KS, Light GA, Geyer M, McDowell JE, Braff DL. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. PMID: 11986147.
      View in: PubMed
    210. Ludewig K, Geyer M, Etzensberger M, Vollenweider FX. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res. 2002 May 01; 55(1-2):129-37. PMID: 11955972.
      View in: PubMed
    211. Martinez-Price DL, Geyer M. Subthalamic 5-HT(1A) and 5-HT(1B) receptor modulation of RU 24969-induced behavioral profile in rats. Pharmacol Biochem Behav. 2002 Apr; 71(4):569-80. PMID: 11888548.
      View in: PubMed
    212. Dirks A, Groenink L, Schipholt MI, van der Gugten J, Hijzen TH, Geyer M, Olivier B. Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry. 2002 Apr 01; 51(7):583-90. PMID: 11950460.
      View in: PubMed
    213. Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs. 2002 Apr-Jun; 34(2):171-84. PMID: 12691207.
      View in: PubMed
    214. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer M, Cadenhead K, Auerbach PP. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl). 2002 May; 161(2):189-201. PMID: 11981599.
      View in: PubMed
    215. Martinez ZA, Platten A, Pollack E, Shoemaker J, Ro H, Pitcher L, Geyer M, Swerdlow NR. "Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats. Psychopharmacology (Berl). 2002 Apr; 161(1):38-46. PMID: 11967629.
      View in: PubMed
    216. Geyer M, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001 Jul; 156(2-3):117-54. PMID: 11549216.
      View in: PubMed
    217. Geyer M, Swerdlow NR, Lehmann-Masten V, Teschendorf HJ, Traut M, Gross G. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. J Pharmacol Exp Ther. 1999 Aug; 290(2):716-24. PMID: 10411583.
      View in: PubMed
    Mark's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _